NEBULISED SALBUTAMOL WITH AND WITHOUT IPRATROPIUM BROMIDE IN ACUTE AIRFLOW OBSTRUCTION

doi:10.1016/S0140-6736(89)90126-8

The Lancet

Volume 333, Issue 8652, 24 June 1989, Pages 1418-1420

https://doi.org/10.1016/S0140-6736(89)90126-8 Get rights and content

Abstract

103 patients with acute airflow obstruction (56 asthma, 47 chronic obstructive pulmonary disease [COPD]) completed a double-blind trial of nebulised bronchodilator treatment in a hospital accident and emergency department. Each patient was randomised to receive either 10 mg of salbutamol nebuliser solution in 2 ml of saline or 10 mg of salbutamol in 2 ml (0·5 mg) of preservative-free ipratropium bromide. Peak flow rate (PFR) was recorded before treatment and 1 hour after beginning nebulised treatment. In 23 asthmatic patients given salbutamol alone PFR rose by a mean 31% 1 hour after treatment whereas in 33 such patients given combined treatment it rose by a mean 77% (95% confidence interval for the difference 8-84%). Patients whose PFR was below 140 1/min at entry gained maximum benefit from the combined treatment. For COPD patients the PFR rise was almost identical for both treatments. In acute asthma the immediate PFR response to a mixture of salbutamol and ipratropium bromide was better than the response to nebulised salbutamol alone. For COPD patients, the two treatments were of equal benefit.

References (16)

DH. Bryant
Nebulised ipratropium bromide in the treatment of acute asthma
Chest
(1985)
R. Beck et al.
Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma
J Pediatr
(1985)
Rm Higgins et al.
Should nebulised ipratropium bromide be added to beta-agonists in acute severe asthma?
Chest
(1988)
As Rebuck et al.
Nebulised anticholinergic and sympathomimetic treatment of obstructive airways disease in the emergency room
Am J Med
(1987)
Brc O'Driscoll et al.
Emergency use of nebulised bronchodilator drugs in British hospitals
Thorax
(1987)
Mj Ward et al.
Ipratropium bromide m acute asthma
Br Med J
(1981)
Mj Ward et al.
A place for ipratropium bromide in the treatment of severe acute asthma
Br J Dis Chest
(1985)

There are more references available in the full text version of this article.

Cited by (158)

How should exacerbations of COPD be managed in the intensive care unit?
2019, Evidence-Based Practice of Critical Care
Chronic obstructive pulmonary disease (COPD) is increasing in prevalence and accounts for up to 10% of acute emergency medical hospital admissions and 2% of nonsurgical referrals to the intensive care unit (ICU). Acute admission with COPD is associated with as high as an 11% acute mortality and 43% 1-year m ortality, and a 50% readmission rate within 6 months. While it is difficult to predict the acute outcome of ICU admissions in COPD, late failure of ward-based care, comorbidities and severe disease may aid in establishing appropriate ceilings of care. Pharmacologic treatment remains corticosteroids, nebulized bronchodilators, and antibiotics. Oxygen should be titrated in a controlled manner in COPD to oxygen saturation of 88–90%. This has been shown to reduce mortality. Noninvasive ventilation has evolved into the most effective treatment for acute hypercapnic respiratory failure, with better outcome in mortality and length of stay compared with invasive ventilation. Clinicians must be aware of barotrauma and dynamic hyperinflation when using positive pressure ventilation in COPD. High-flow nasal oxygen is evolving as an effective therapy to assist extubation as well as treat acute respiratory failure in COPD. Further studies are required. End-of-life decisions can be assisted by early discussion in those with severe disease, especially with comorbid illness, and in those with prolonged intubation over 72 hours and failed extubation. Some studies have shown that patients with COPD describe same or improved quality of life after invasive ventilation in the ICU; so it can be difficult to predict impact and outcomes.
Chronic obstructive pulmonary disease: A guide for the primary care physician
2016, Disease-a-Month
Citation Excerpt :
Anticholinergic agents such as ipratropium bromide are also effective bronchodilators which are used in combination with short-acting beta adrenergic agonists.128 It has been shown that a combination of short-acting–beta adrenergic agonists and short-acting anticholinergic agents produce a greater degree of bronchodilation than either agent when used alone.129,130 Systemic steroids have been proven useful during acute exacerbations.
Inhaled and intravenous treatment in acute severe and life-threatening asthma
2013, British Journal of Anaesthesia
Citation Excerpt :
In severe asthma paediatricians will use up to 12 actuations into a spacer before a single inhalation by the patient. Disposable jet or ‘wet' nebulizers with oxygen as driving gas also rely on inhalation by an awake, co-operative patient and deliver salbutamol 2.5 mg in 2.5 ml, or 5 mg in 2.5 ml, diluted to 10 ml with normal saline delivered over 20 min; the addition of ipratropium bromide 500 µg will produce peak bronchodilator response.8 BTS recommends back-to-back nebulization of these two drugs over 20 min, that is, 3 in 1 h. Guidelines do not distinguish between the different nebulizers available and only give undiluted doses of nebulizer solutions; dilution is required in order to maintain nebulized solution production over a 20 min period (Table 1).
Management of life-threatening acute severe asthma in children and adults may require anaesthetic and intensive care. The inhaled route for drug delivery is not appropriate when only small respiratory gas volumes are shifted; the i.v. route may be associated with greater side-effects. Magnesium sulphate i.v. has a place in acute asthma management because it is a mild bronchodilator, and has a stabilizing effect on the atria which may attenuate tachycardia occurring after inhaled and i.v. salbutamol. If intubation and ventilation are required, a reduction in bronchoconstriction by any means before and during these procedures should reduce morbidity. This narrative review aims to show strengths and weakness of the evidence, present controversies, and forward opinions of the author. The review contains a practical guide to the setting up, use and efficiency of nebulizers, metered dose inhalers, and spacers (chambers). It also presents a commonsense approach to the management of severe asthmatics in whom delay in bronchodilatation would cause clinical deterioration. When self-inhaled agents have had no effect, i.v. drugs may help avoid intubation and ventilation. The review includes suggestions for the use of inhaled anaesthetics, anaesthetic induction, and brief notes on subsequent ventilation of the lungs.
How Should Exacerbations of COPD Be Managed in the Intensive Care Unit?
2010, Evidence-Based Practice of Critical Care: Expert Consult: Online and Print
How Should Exacerbations of COPD Be Managed in the Intensive Care Unit
2010, Evidence-Based Practice of Critical Care
Life-Threatening Asthma
2008, Critical Care Medicine: Principles of Diagnosis and Management in the Adult

View all citing articles on Scopus

View full text

NEBULISED SALBUTAMOL WITH AND WITHOUT IPRATROPIUM BROMIDE IN ACUTE AIRFLOW OBSTRUCTION

Abstract

Chest

J Pediatr

Chest

Am J Med

Emergency use of nebulised bronchodilator drugs in British hospitals

Thorax

Ipratropium bromide m acute asthma

Br Med J

A place for ipratropium bromide in the treatment of severe acute asthma

Br J Dis Chest